{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aerovate Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AVTE"},"Address":{"label":"Address","value":"930 WINTER STREET,SUITE M-500, WALTHAM, Massachusetts, 02116, United States"},"Phone":{"label":"Phone","value":"+1 617 443-2400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe."},"CompanyUrl":{"label":"Company Url","value":"https://www.aerovatetx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Benjamin T. Dake","title":"President, Chief Operating Officer & Secretary"},{"name":"Hunter Gillies","title":"Chief Medical Officer"},{"name":"Marco Verwijs","title":"Chief Technical Officer"},{"name":"Ralph Niven","title":"Chief Scientific Officer"},{"name":"Timothy P. Noyes","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}